

SHORT COMMUNICATION

Intracerebroventricular Endothelin Receptor-A Blockade in Rats Decreases Phase-II Ventricular Tachyarrhythmias During Acute Myocardial Infarction

P. LEKKAS^{1,2}, E. S. GEORGIU¹, M. KONTONIKA¹, E.-T. MOUCHTOURI^{1,2},
I. MOUROUZIS³, C. PANTOS³, T. M. KOLETTIS^{1,2}

¹Cardiovascular Research Institute, University of Ioannina, Ioannina, Greece, ²Department of Cardiology, Medical School, University of Ioannina, Ioannina, Greece, ³Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Received February 4, 2019

Accepted May 7, 2019

Epub Ahead of Print August 19, 2019

Summary

Endothelin alters central sympathetic responses, but the resultant effects on arrhythmogenesis are unknown. We examined ventricular tachyarrhythmias after endothelin receptor-A blockade in the brain of Wistar rats with acute myocardial infarction. For this aim, BQ-123 (n=6) or phosphate-buffered saline (n=6) were injected intracerebroventricularly. After 10 min, the left coronary artery was ligated, followed by implantation of telemetry transmitters. Electrocardiography and voluntary activity (as a surrogate of acute left ventricular failure) were continuously monitored for 24 h. Infarct-size was similar in the two groups. There were fewer episodes of ventricular tachyarrhythmias of shorter average duration in treated rats, leading to markedly shorter total duration (12.3±8.9 s), when compared to controls (546.2±130.3 s). Voluntary activity increased in treated rats during the last hours of recording, but bradyarrhythmic episodes were comparable between the two groups. Endothelin receptor-A blockade in the brain of rats decreases the incidence of ventricular tachyarrhythmias post-ligation, without affecting bradyarrhythmic episodes. These findings call for further research on the pathophysiologic role of endothelin during acute myocardial infarction.

Key words

Myocardial infarction • Brain • Endothelin • A-receptor • Ventricular tachyarrhythmias

Corresponding author

T. M. Kolettis, Cardiovascular Research Institute, University of Ioannina, 1 Stavrou Niarxou Avenue, 45500 Ioannina, Greece. Fax: +30(265)1007053. E-mail: thofilos.m.kolettis@gmail.com

Acute myocardial infarction (MI) is often complicated by ventricular tachyarrhythmias (VTs) that occur during the early stage of ischemia, or subsequently, during evolving MI (Kolettis 2013). The latter VTs, referred to as phase-II arrhythmogenesis, have an ominous prognosis not only in the out-of-hospital setting, but also in hospitalized patients (Piccini *et al.* 2008).

Central sympathetic activation, occurring frequently during acute MI, contributes to the genesis of phase-II VTs (Kolettis 2018). Despite continuing research on this topic, the underlying pathophysiology remains incompletely understood. Endothelin-1 (ET-1) has attracted considerable interest in this regard, with its actions as a mediator of central sympathetic responses reported shortly after its discovery (Ouchi *et al.* 1989). For instance, intracerebroventricular (i.c.v.) injections of ET-1 in rats were shown to alter heart rate (HR) and plasma catecholamines (Kuwaki *et al.* 1997). These actions are likely exerted *via* ETA-receptors, which are abundantly located in central neurons (Mosqueda-Garcia *et al.* 1993). The present study, performed in the rat-model of acute MI, explored the hypothesis that ETA-receptor blockade in the brain decreases the

incidence of phase-II VTs.

The experiments were conducted on 12 Wistar rats (258±7 g), housed under optimal conditions. The study was approved by the institutional ethics' committee and adheres to the European guidelines on laboratory animal care. The rats were mechanically ventilated at 85 breaths/min and anesthetized with 2.5 %-sevoflurane, a regimen not affecting autonomic responses (Kurosawa *et al.* 1989). They were placed on a stereotaxic frame (David Kopf, CA, USA), and 10 µl of phosphate-buffered saline (PBS) was slowly (10 min) injected i.c.v. via a Hamilton-needle, according to previous guides (DeVos and Miller 2013). The following coordinates were used relative to the bregma: 1.08 mm anteroposteriorly, ±1.9 mm mediolaterally and -3.7 mm dorsoventrally. Based on previous data (Mosqueda-Garcia *et al.* 1993), the injections contained 10 nmol of (the selective ETA-receptor antagonist) BQ-123 (directly dissolved in

PBS) in the treatment group, with only PBS in controls; 10 min thereafter, the left coronary artery was permanently ligated midway between its origin and the apex, with the induced MI validated by ST-segment elevation in a 6-lead ECG. After 30 min, telemetry-transmitters (TCA-F40, DSI, MN, USA) were implanted quickly (<10 min) in survivors. The opioid-analgesic buprenorphine (0.05 mg/kg) was injected intraperitoneally prior to extubation in both groups, thus eliminating pain as a confounding factor. The protocol, depicted in Fig. 1, (i.c.v. administration, anesthesia, analgesia) ensures the comparability between the two groups. The rats regained consciousness within 3 min after discontinuation of anesthesia, and were then placed on a receiver (RCA-1020, DSI), capturing the signal continuously for 24 h; this setting enables the assessment in the conscious, unrestrained state.




Fig. 1. The study-protocol included, (1) intubation (2) intracerebroventricular injections, (3) induction of myocardial infarction, (4) implantation of telemetry-recorders, (5) 24 h ECG-recording in conscious animals, (6) measurement of infarct-size, and (7) arrhythmia-analysis.

Premature ventricular contractions, couplets and triplets were counted in the treatment and control groups, each of n=6 animals. The number and duration of VT-episodes, as well as bradyarrhythmic events were also recorded. Lastly, voluntary motor-activity was assessed by the number of counts, generated by strength-variations in telemetry-signal, relative to animal location; these counts correlate with the incidence and severity of acute left ventricular (LV) failure (Howarth *et al.* 2006). Based on previous work in rats, showing voluntary activity to occur mainly after the 10th hour post-MI (Kolettis *et al.* 2014), values are given separately for the

early (initial 10 h) and delayed periods (last 14 h of recording). Mean sinus HR was calculated separately for these periods and for the entire experiment. At the end, infarct-size was measured by planimetry (ImageJ, NIH, USA) after triphenyltetrazolium-chloride staining, as described previously (Oikonomidis *et al.* 2010).

Values are reported as mean ± standard error of the mean; after examination for normality with the Kolmogorov-Smirnov test, the variables displaying skewed distribution were transformed according to Box-Cox analysis. Subsequently, differences between the two groups were assessed with the Student's *t*-test, whereas

changes over time were assessed with analysis of variance for repeated measures, followed by *post hoc* Duncan's test. Statistical significance was set at $p < 0.05$.

Infarct-size (as % of LV area) was similar between treated rats (28.7 ± 1.9) and controls (27.3 ± 1.6). HR remained stable in controls throughout the 24 h-period, but it increased during the delayed stage in the treatment group (Fig. 2A). The total number of

bradyarrhythmic episodes was comparable, namely 52 ± 23 in treated rats and 32 ± 11 in controls; likewise, the total duration of these episodes did not differ, being 28.8 ± 12.3 s and 17.1 ± 5.6 s, respectively. The total number of premature ventricular contractions was also similar, at 125 ± 63 in the treatment group and 207 ± 52 in controls, but fewer couplets were observed in the treatment group (6 ± 3) than in controls (13 ± 2).




Fig. 2. Heart rate (A) and voluntary activity (B) increased (asterisks, denoting $p=0.0032$ and $p=0.025$, respectively) in treated rats (solid squares) during the delayed period (last 14 h of the recording), but remained stable in controls (open circles). In treated rats, there were fewer episodes (C, $p=0.0058$) of ventricular tachyarrhythmias (VTs) of shorter average duration, resulting in lower ($p=0.00075$) total duration (D).

There were fewer VT-episodes in treated rats (8 ± 5) than in controls (68 ± 25 , Fig. 2B); moreover, the average duration of each episode was shorter in treated animals (0.7 ± 0.4 s) than in controls (11.3 ± 3.6 s). As a result, the total duration of VTs was markedly shorter in the treatment group (12.3 ± 8.9 s) than in controls (546.2 ± 130.3 s, Fig. 2C). Compared to the early phase, voluntary activity increased in both groups during the delayed time-period, but such increase was more pronounced in treated rats (Fig. 2D).

Acute MI is often complicated by VTs, with highest incidence during the initial 24 h. Here, we investigated the antiarrhythmic potential of ETA-receptor blockade in the brain of rats; this model is considered particularly useful, as the rat displays multiple VT-episodes in response to coronary ligation (Opitz *et al.* 1995), thereby maximizing the yield of each experiment. Central ETA-receptor blockade was achieved by i.c.v. injections in the lateral ventricles, with this route favored over systemic administration, based on the absence of firm data on the blood-brain barrier permeability of ETA-receptor blockers. This setting is commonly used in

the assessment of compounds with potential central cardiovascular activity, as they can act on many structures after spreading throughout the brain (Dashwood and Loesch 2010). However, its major drawback lies within the inability to accurately identify the responsible nuclei, thus necessitating additional studies. The 24 h-period in our protocol encompassed phase-II arrhythmogenesis, which remains an important therapeutic target, as such VTs coincide with evolving MI and terminate after the completion of the necrosis wavefront (Janse and Wit 1989). As in previous work (Opitz *et al.* 1995), we observed multiple VT-episodes in the control group, ceasing after the 10th h post-MI.

The main finding of the present study was the markedly lower incidence of VTs in treated rats. Interestingly, this difference resulted from *fewer* episodes of *shorter duration*, supporting the hypothesis of ameliorated central sympathetic activation as the underlying mechanism. Indeed, central sympathetic responses, evident invariably after the 1st h post-MI (Jardine *et al.* 2005), are implicated in the genesis of phase-II VTs (Kolettis *et al.* 2018), mediated by

enhanced focal automaticity and delayed afterdepolarizations (Di Diego and Antzelevitch 2011). Additionally, sympathetic stimulation shortens the effective refractory period in the non-ischemic zone, which is simultaneously prolonged in the ischemic area (Ophthof *et al.* 1993); these opposite effects may enhance myocardial inhomogeneity, favoring reentry.

The observed antiarrhythmic effect of central ETA-receptor blockade during phase-II is in concert with previous findings, demonstrating ET-1 as an important modulator of sympathetic activity at the myocardial and adrenal levels (Kolettis *et al.* 2013). Our findings, in the absence of the confounding effects of anesthesia and pain, reinforce previous suggestions on ET-1 as a regulator of central sympathetic responses (Dashwood and Loesch 2010). This intriguing hypothesis merits further investigation that could shed light to the function of ET-1 as a neurotransmitter and/or as a vasoconstrictor of cerebral arteries. Moreover, the pathophysiologic role of ETB-receptors during acute MI deserves particular attention, as these are widely distributed in high density across glial-cells of rats and humans (Morton and Davenport 1992).

Further to VTs, our analysis included

bradyarrhythmic episodes, based on previously reported atrioventricular-block, counterbalancing the antiarrhythmic effect of decreased central sympathetic activity (Kolettis *et al.* 2015). Such episodes reflect not only conduction properties, but they are considered also indicative of acute LV failure in the rat-model (Opitz *et al.* 1995). In our experiments, bradyarrhythmic episodes did not differ between treated rats and controls, suggesting absence of treatment-effects on atrioventricular-conduction. This finding may reflect enhanced voluntary activity in the treated group, a statement supported by the higher activity counts and HR in this cohort during the delayed post-MI phase. Thus, the effects of central ETA-receptor blockade on the incidence of LV failure may constitute target for future research.

In summary, our study shows that ETA-receptor blockade in the brain decreases delayed VTs during acute MI in rats, without concurrent bradyarrhythmia. These preliminary findings justify further research on the effects of ET-1 on autonomic responses during acute MI.

Conflict of Interest

There is no conflict of interest.

References

- CASSINOTTI LR, GUIL MJ, SCHOLLER MI, NAVARRO MP, BIANCIOTTI LG, VATTA MS: Chronic blockade of brain endothelin receptor type-A (ETA) reduces blood pressure and prevents catecholaminergic overactivity in the right olfactory bulb of DOCA-salt hypertensive rats. *Int J Mol Sci* **19**: E660, 2018.
- DASHWOOD MR, LOESCH A: Endothelin-1 as a neuropeptide: neurotransmitter or neurovascular effects? *J Cell Commun Signal* **4**: 51-62, 2010.
- DEVOS S, MILLER TM: Direct intraventricular delivery of drugs to the rodent central nervous system. *J Vis Exp* **12**: e50326, 2013.
- DI DIEGO JM, ANTZELEVITCH C: Ischemic ventricular arrhythmias: experimental models and their clinical relevance. *Heart Rhythm* **8**: 1963-1968, 2011.
- HOWARTH FC, JACOBSON M, SHAFIULLAH M, ADEGHATE E: Effects of insulin treatment on heart rhythm, body temperature and physical activity in streptozotocin-induced diabetic rat. *Clin Exp Pharmacol Physiol* **33**: 327-331, 2006.
- JANSE MJ, WIT AL: Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. *Physiol Rev* **69**: 1049-1169, 1989.
- JARDINE DL, CHARLES CJ, ASHTON RK, BENNETT SI, WHITEHEAD M, FRAMPTON CM, NICHOLLS MG: Increased cardiac sympathetic nerve activity following acute myocardial infarction in a sheep model. *J Physiol* **565**: 325-333, 2005.
- KOLETTIS TM, BARTON M, LANGLEBEN D, MATSUMURA Y: Endothelin in coronary artery disease and myocardial infarction. *Cardiol Rev* **21**: 249-256, 2013.
- KOLETTIS TM: Coronary artery disease and ventricular tachyarrhythmia: pathophysiology and treatment. *Curr Opin Pharmacol* **13**: 210-217, 2013.

- KOLETTIS TM, KONTONIKA M, VALENTI MC, VILAETI AD, BALTOGIANNIS GG, PAPALOIS A, KYRIAKIDES ZS: Arrhythmogenesis after acute myocardial necrosis with and without preceding ischemia in rats. *J Basic Clin Physiol Pharmacol* **25**: 143-153, 2014.
- KOLETTIS TM, KONTONIKA M, BARKA E, DASKALOPOULOS EP, BALTOGIANNIS GG, TOURMOUSOGLU C, PAPALOIS A, KYRIAKIDES ZS: Central sympathetic activation and arrhythmogenesis during acute myocardial infarction: modulating effects of endothelin-B receptors. *Front Cardiovasc Med* **2**: 6, 2015.
- KOLETTIS TM, KONTONIKA M, LEKKAS P, VLAHOS AP, BALTOGIANNIS GG, GATZOULIS KA, CHROUSOS GP: Autonomic responses during acute myocardial infarction in the rat model: implications for arrhythmogenesis. *J Basic Clin Physiol Pharmacol* **29**: 339-345, 2018.
- KOLETTIS TM: Autonomic function and ventricular tachyarrhythmias during acute myocardial infarction. *World J Exp Med* **8**: 8-11, 2018.
- KUROSAWA M, MEGURO K, NAGAYAMA T, SATO A: Effects of sevoflurane on autonomic nerve activities controlling cardiovascular functions in rats. *J Anesth* **3**: 109-117, 1989.
- KUWAKI T, KURIHARA H, CAO WH, KURIHARA Y, UNEKAWA M, YAZAKI Y, KUMADA M: Physiological role of brain endothelin in the central autonomic control: from neuron to knockout mouse. *Prog Neurobiol* **51**: 545-579, 1997.
- MORTON AJ, DAVENPORT AP: Cerebellar neurons and glia respond differentially to endothelins and sarafotoxin S6b. *Brain Res* **581**: 299-306, 1992.
- MOSQUEDA-GARCIA R, INAGAMI T, APPALSAMY M, SUGIURA M, ROBERTSON RM: Endothelin as a neuropeptide. Cardiovascular effects in the brainstem of normotensive rats. *Circ Res* **72**: 20-35, 1993.
- OIKONOMIDIS DL, TSALIKAKIS DG, BALTOGIANNIS GG, TZALLAS AT, XOURGIA X, AGELAKI MG, MEGALOU AJ, FOTOPOULOS A, PAPALOIS A, KYRIAKIDES ZS, KOLETTIS TM: Endothelin-B receptors and ventricular arrhythmogenesis in the rat model of acute myocardial infarction. *Basic Res Cardiol* **105**: 235-245, 2010.
- OPITZ CF, MITCHELL GF, PFEFFER MA, PFEFFER JM: Arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats. *Circulation* **92**: 253-261, 1995.
- OPTHOF T, CORONEL R, VERMEULEN JT, VERBERNE HJ, VAN CAPELLE FJ, JANSE MJ: Dispersion of refractoriness in normal and ischaemic canine ventricle: effects of sympathetic stimulation. *Cardiovasc Res* **27**: 1954-1960, 1993.
- OUCHI Y, KIM S, SOUZA AC, IJIMA S, HATTORI A, ORIMO H, YOSHIZUMI M, KURIHARA H, YAZAKI Y: Central effect of endothelin on blood pressure in conscious rats. *Am J Physiol* **256**: H1747-H1751, 1989.
- PICCINI JP, BERGER JS, BROWN DL: Early sustained ventricular arrhythmias complicating acute myocardial infarction. *Am J Med* **121**: 797-804, 2008.
-